United Therapeutics Corporation (UTHR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in United Therapeutics Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

United Therapeutics Corporation (UTHR) has returned 21.70% so far this year and 92.36% over the past 12 months. Looking at the last ten years, UTHR has achieved an annualized return of 18.04%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Jun 17, 1999, UTHR's average daily return is +0.11%, while the average monthly return is +2.43%. At this rate, your investment would double in approximately 2.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Jun 2000 with a return of +71.0%, while the worst month was Dec 2000 at -69.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, UTHR closed higher 51% of trading days. The best single day was Aug 10, 2001 with a return of +58.9%, while the worst single day was Dec 4, 2000 at -62.3%.

United Therapeutics Corporation has an annualized alpha of 26.09%, beta of 0.73, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 18, 1999.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (88.19%) than losses (27.02%) — typical of diversified or defensive assets.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

UTHR ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of United Therapeutics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how United Therapeutics Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.